Skeletal muscle inflammation and insulin resistance in obesity

Journal of Clinical Investigation

Volumn 127, Issue 1, 2017, Pages 43-54

  Wu, Huaizhu ^a,b   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Department of Pediatrics ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FATTY ACID; JANUS KINASE; LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; GLUCOSE;

ARTICLE; CELL ACTIVATION; CELLULAR SECRETION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; INSULIN RESISTANCE; MUSCLE CELL; MYOSITIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; COMPLICATION; IMMUNOLOGY; INFLAMMATION; INTRAABDOMINAL FAT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; SKELETAL MUSCLE CELL;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOSITIS; OBESITY;

EID: 85008343699     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI88880     Document Type: Article

References (168)

1. Poirier P, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898-918.
2. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016;12(1):15-28.
3. Centers for Disease Control and Prevention. Diabetes Public Health Resource. CDC Web site. http://www.cdc.gov/diabetes/statistics/prev/national/figadults.htm. Updated December 1, 2015. Accessed October 20, 2016.
4. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111-2117.
5. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363-374.
6. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014;41(1):36-48.
7. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
8. Chawla A, Nguyen KD, Goh YP. Macrophagemediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11(11):738-749.
9. Wu H, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation. 2007;115(8):1029-1038.
10. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367-377.
11. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-246.
12. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-871.
13. Wu H, Ballantyne CM. Inflammation versus host defense in obesity. Cell Metab. 2014;20(5):708-709.
14. Petersen KF, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A. 2007;104(31):12587-12594.
15. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol. 2002;90(5A):11G-18G.
16. Lorenzo M, Fernandez-Veledo S, Vila-Bedmar R, Garcia-Guerra L, De Alvaro, C, Nieto-Vazquez I. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci. 2008;86(14 suppl):E94-E104.
17. Bouzakri K, Koistinen HA, Zierath JR. Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes. Curr Diabetes Rev. 2005;1(2):167-174.
18. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(suppl 2):S157-S163.
19. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457-465.
20. Eckardt K, Gorgens SW, Raschke S, Eckel J. Myokines in insulin resistance and type 2 diabetes. Diabetologia. 2014;57(6):1087-1099.
21. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev. 2006;12:6-33.
22. Carey AL, et al. Interleukin-6 increases insulin- stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55(10):2688-2697.
23. Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol. 2006;20(12):3364-3375.
24. Rodriguez A, Becerril S, Ezquerro S, Mendez- Gimenez L, Fruhbeck G. Cross-talk between adipokines myokines in fat browning [published online ahead of print April 4, 2016]. Acta Physiol (Oxf). doi:10.1111/apha.12686.
25. Wolsk E, Mygind H, Grondahl TS, Pedersen BK, van Hall, G. IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am J Physiol Endocrinol Metab. 2010;299(5):E832-E840.
26. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. FASEB J. 2003;17(8):884-886.
27. Vaughan RA, et al. Characterization of the metabolic effects of irisin on skeletal muscle in vitro. Diabetes Obes Metab. 2014;16(8):711-718.
28. Bostrom P, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-468.
29. Lee P, et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014;19(2):302-309.
30. Shin KO, et al. The effect of exercise on expression of myokine and angiogenesis mRNA in skeletal muscle of high fat diet induced obese rat. J Exerc Nutrition Biochem. 2015;19(2):91-98.
31. Green CJ, Pedersen M, Pedersen BK, Scheele C. Elevated NF-κB activation is conserved in human myocytes cultured from obese type 2 diabetic patients and attenuated by AMP-activated protein kinase. Diabetes. 2011;60(11):2810-2819.
32. Reyna SM, et al. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes. 2008;57(10):2595-2602.
33. Corpeleijn E, Saris WH, Jansen EH, Roekaerts PM, Feskens EJ, Blaak EE. Postprandial interleukin-6 release from skeletal muscle in men with impaired glucose tolerance can be reduced by weight loss. J Clin Endocrinol Metab. 2005;90(10):5819-5824.
34. Ciaraldi TP, Ryan AJ, Mudaliar SR, Henry RR. Altered myokine secretion is an intrinsic property of skeletal muscle in type 2 diabetes. PLoS One. 2016;11(7):e0158209.
35. Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond). 2015;39(11):1607-1618.
36. Varma V, et al. Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab. 2009;296(6):E1300-E1310.
37. Patsouris D, et al. Insulin resistance is associated with MCP1-mediated macrophage accumulation in skeletal muscle in mice and humans. PLoS One. 2014;9(10):e110653.
38. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest. 1996;97(4):1111-1116.
39. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens. 2000;18(11):1605-1610.
40. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A. siRNA-mediated reduction of inhibitor of nuclear factor-κB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes. 2008;57(8):2066-2073.
41. Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro, C, Rondinone CM, Valverde AM, Lorenzo M. Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-α-induced insulin resistance. Diabetes. 2007;56(2):404-413.
42. del Aguila, LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol. 1999;276(5 pt 1):E849-E855.
43. Zhang Y, et al. MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by targeting mitofusin-2. Mol Cell Endocrinol. 2013;381(1-2):230-240.
44. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54(10):2939-2945.
45. de Alvaro, C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor α produces insulin resistance in skeletal muscle by activation of inhibitor κB kinase in a p38 MAPK-dependent manner. J Biol Chem. 2004;279(17):17070-17078.
46. Wu H, et al. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol. 2010;30(2):186-192.
47. Nguyen MT, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem. 2007;282(48):35279-35292.
48. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-184.
49. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808.
50. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15(5):635-645.
51. Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity- related insulin resistance. J Clin Invest. 2003;112(12):1821-1830.
52. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, Sowers JR. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol. 2008;294(3):R673-R680.
53. Fink LN, et al. Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans. Obesity (Silver Spring). 2014;22(3):747-757.
54. Torres SH, De Sanctis JB, de Briceno, M, Hernandez N, Finol HJ. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol. 2004;181(3):419-427.
55. Fink LN, et al. Expression of anti-inflammatory macrophage genes within skeletal muscle correlates with insulin sensitivity in human obesity and type 2 diabetes. Diabetologia. 2013;56(7):1623-1628.
56. Boon MR, et al. Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. Clin Sci. 2015;128(2):143-151.
57. Tam CS, et al. Weight gain reveals dramatic increases in skeletal muscle extracellular matrix remodeling. J Clin Endocrinol Metab. 2014;99(5):1749-1757.
58. Wang J, et al. ApoE and the role of very low density lipoproteins in adipose tissue inflammation. Atherosclerosis. 2012;223(2):342-349.
59. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008;8(4):301-309.
60. Hong EG, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. 2009;58(11):2525-2535.
61. Lee YS, et al. Inflammation is necessary for longterm but not short-term high-fat diet-induced insulin resistance. Diabetes. 2011;60(10):2474-2483.
62. Hevener AL, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest. 2007;117(6):1658-1669.
63. Altintas MM, et al. Leptin deficiency-induced obesity affects the density of mast cells in abdominal fat depots and lymph nodes in mice. Lipids Health Dis. 2012;11:21.
64. Talukdar S, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med. 2012;18(9):1407-1412.
65. Kelley DE, Goodpaster BH. Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care. 2001;24(5):933-941.
66. Santanasto AJ, Newman AB, Strotmeyer ES, Boudreau RM, Goodpaster BH, Glynn NW. Effects of changes in regional body composition on physical function in older adults: a pilot randomized controlled trial. J Nutr Health Aging. 2015;19(9):913-921.
67. Albu JB, et al. Independent association of insulin resistance with larger amounts of intermuscular adipose tissue and a greater acute insulin response to glucose in African American than in white nondiabetic women. Am J Clin Nutr. 2005;82(6):1210-1217.
68. Goodpaster BH, Thaete FL, Kelley DE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr. 2000;71(4):885-892.
69. Haam JH, et al. Intermuscular adipose tissue is associated with monocyte chemoattractant protein-1, independent of visceral adipose tissue. Clin Biochem. 2016;49(6):439-443.
70. Scott D, et al. Associations of calf inter- And intra-muscular adipose tissue with cardiometabolic health and physical function in communitydwelling older adults. J Musculoskelet Neuronal Interact. 2015;15(4):350-357.
71. Di Gregorio, GB, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes. 2005;54(8):2305-2313.
72. Tam CS, Sparks LM, Johannsen DL, Covington JD, Church TS, Ravussin E. Low macrophage accumulation in skeletal muscle of obese type 2 diabetics and elderly subjects. Obesity (Silver Spring). 2012;20(7):1530-1533.
73. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2006;290(5):E961-E967.
74. Brake DK, Smith EO, Mersmann H, Smith CW, Robker RL. ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice. Am J Physiol Cell Physiol. 2006;291(6):C1232-C1239.
75. Chen A, et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res. 2005;13(8):1311-1320.
76. Evers-van Gogh IJ, et al. Muscle-specific inflammation induced by MCP-1 overexpression does not affect whole-body insulin sensitivity in mice. Diabetologia. 2016;59(3):624-633.
77. Kitade H, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes. 2012;61(7):1680-1690.
78. Li P, et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015;21(3):239-247.
79. Jiang E, et al. Essential role of CD11a in CD8+ T-cell accumulation and activation in adipose tissue. Arterioscler Thromb Vasc Biol. 2014;34(1):34-43.
80. Oh DY, Morinaga H, Talukdar S, Bae EJ, Olefsky JM. Increased macrophage migration into adipose tissue in obese mice. Diabetes. 2012;61(2):346-354.
81. Wu H, et al. Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation. 2009;119(20):2708-2717.
82. Tacke F, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117(1):185-194.
83. Xu L, et al. Foamy monocytes form early and contribute to nascent atherosclerosis in mice with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2015;35(8):1787-1797.
84. Morris DL, et al. Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice. Diabetes. 2013;62(8):2762-2772.
85. Amano SU, et al. Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metab. 2014;19(1):162-171.
86. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787-795.
87. Rocha VZ, et al. Interferon-γ, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res. 2008;103(5):467-476.
88. Arkan MC, et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11(2):191-198.
89. Chiang SH, et al. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell. 2009;138(5):961-975.
90. Reilly SM, et al. An inhibitor of the protein kinases TBK1 and IKK-ϵ improves obesityrelated metabolic dysfunctions in mice. Nat Med. 2013;19(3):313-321.
91. Hirosumi J, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333-336.
92. Han MS, et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science. 2013;339(6116):218-222.
93. Solinas G, et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007;6(5):386-397.
94. Deng T, et al. Class II major histocompatibility complex plays an essential role in obesityinduced adipose inflammation. Cell Metab. 2013;17(3):411-422.
95. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015-3025.
96. Vandanmagsar B, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179-188.
97. Li N, Fu J, Koonen DP, Kuivenhoven JA, Snieder H, Hofker MH. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? Atherosclerosis. 2014;233(1):130-138.
98. Furtado JD, et al. Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the Omni Heart Trial. Am J Clin Nutr. 2008;87(6):1623-1630.
99. Benetti E, et al. High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: a protective role for PPAR-δ agonism. Mediators Inflamm. 2013;2013:509502.
100. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297(2):E271-E288.
101. Ferreira LD, Pulawa LK, Jensen DR, Eckel RH. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes. 2001;50(5):1064-1068.
102. Kim JK, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001;98(13):7522-7527.
103. Wang H, et al. Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes. 2009;58(1):116-124.
104. Goossens GH, Blaak EE, Arner P, Saris WH, van Baak, MA. Angiotensin II: a hormone that affects lipid metabolism in adipose tissue. Int J Obes (Lond). 2007;31(2):382-384.
105. Kalupahana NS, et al. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring). 2012;20(1):48-56.
106. Hahn AW, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 1994;347(2-3):178-180.
107. Tummala PE, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation. 1999;100(11):1223-1229.
108. Lastra G, Sowers JR. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system. Horm Mol Biol Clin Investig. 2013;15(2):49-57.
109. Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F. Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med Res Rev. 2015;35(3):437-463.
110. Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 2013;15(1):59-70.
111. Kalupahana NS, Voy BH, Saxton AM, Moustaid-Moussa N. Energy-restricted high-fat diets only partially improve markers of systemic and adipose tissue inflammation. Obesity (Silver Spring). 2011;19(2):245-254.
112. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21(1):20-27.
113. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab. 2008;294(2):E345-E351.
114. Premaratna SD, et al. Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice. Int J Obes (Lond). 2012;36(2):233-243.
115. Marcus Y, et al. Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes. 2013;62(4):1121-1130.
116. Patel VB, et al. ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes. 2016;65(1):85-95.
117. Radin MS, Sinha S, Bhatt BA, Dedousis N, O'Doherty RM. Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia. 2008;51(2):336-346.
118. Henriksen EJ, Prasannarong M. The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. Mol Cell Endocrinol. 2013;378(1-2):15-22.
119. Goossens GH, Blaak EE, Saris WH, van Baak, MA. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab. 2004;89(6):2690-2696.
120. Williams IM, Otero YF, Bracy DP, Wasserman DH, Biaggioni I, Arnold AC. Chronic angiotensin-( 1-7) improves insulin sensitivity in high-fat fed mice independent of blood pressure. Hypertension. 2016;67(5):983-991.
121. Yuan M, et al. Reversal of obesity- And diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science. 2001;293(5535):1673-1677.
122. Jove M, Planavila A, Sanchez RM, Merlos M, Laguna JC, Vazquez-Carrera M. Palmitate induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-κB activation. Endocrinology. 2006;147(1):552-561.
123. Kim JK, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108(3):437-446.
124. Gao Z, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J Biol Chem. 2002;277(50):48115-48121.
125. Rohl M, et al. Conditional disruption of IκB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest. 2004;113(3):474-481.
126. Cai D, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285-298.
127. Sabio G, Davis RJ. cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance. Trends Biochem Sci. 2010;35(9):490-496.
128. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin- resistant human skeletal muscle. Diabetes. 2005;54(8):2351-2359.
129. Senn JJ. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem. 2006;281(37):26865-26875.
130. Vijayvargia R, Mann K, Weiss HR, Pownall HJ, Ruan H. JNK deficiency enhances fatty acid utilization and diverts glucose from oxidation to glycogen storage in cultured myotubes. Obesity (Silver Spring). 2010;18(9):1701-1709.
131. Santos FR, Diamond-Stanic MK, Prasannarong M, Henriksen EJ. Contribution of the serine kinase c-Jun N-terminal kinase (JNK) to oxidant-induced insulin resistance in isolated rat skeletal muscle. Arch Physiol Biochem. 2012;118(5):231-236.
132. Sabio G, et al. Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulin resistance. Mol Cell Biol. 2010;30(1):106-115.
133. Pal M, Wunderlich CM, Spohn G, Bronneke HS, Schmidt-Supprian M, Wunderlich FT. Alteration of JNK-1 signaling in skeletal muscle fails to affect glucose homeostasis and obesity-associated insulin resistance in mice. PLoS One. 2013;8(1):e54247.
134. Talbot NA, Wheeler-Jones CP, Cleasby ME. Palmitoleic acid prevents palmitic acid-induced macrophage activation and consequent p38 MAPKmediated skeletal muscle insulin resistance. Mol Cell Endocrinol. 2014;393(1-2):129-142.
135. Diamond-Stanic MK, Marchionne EM, Teachey MK, Durazo DE, Kim JS, Henriksen EJ. Critical role of the transient activation of p38 MAPK in the etiology of skeletal muscle insulin resistance induced by low-level in vitro oxidant stress. Biochem Biophys Res Commun. 2011;405(3):439-444.
136. Schmitz-Peiffer C, Biden TJ. Protein kinase C function in muscle, liver, and β-cells and its therapeutic implications for type 2 diabetes. Diabetes. 2008;57(7):1774-1783.
137. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes. 2002;51(7):2005-2011.
138. Szendroedi J, et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc Natl Acad Sci U S A. 2014;111(26):9597-9602.
139. Itani SI, Pories WJ, Macdonald KG, Dohm GL. Increased protein kinase C θ in skeletal muscle of diabetic patients. Metab Clin Exp. 2001;50(5):553-557.
140. Schmitz-Peiffer C, et al. Alterations in the expression and cellular localization of protein kinase C isozymes ϵ and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes. 1997;46(2):169-178.
141. Kewalramani G, Fink LN, Asadi F, Klip A. Palmitate- Activated macrophages confer insulin resistance to muscle cells by a mechanism involving protein kinase C θ and ϵ. PLoS One. 2011;6(10):e26947.
142. Kim JK, et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest. 2004;114(6):823-827.
143. Li M, Vienberg SG, Bezy O, O'Neill BT, Kahn CR. Role of PKCδ in insulin sensitivity and skeletal muscle metabolism. Diabetes. 2015;64(12):4023-4032.
144. Li Y, et al. Protein kinase C θ inhibits insulin signaling by phosphorylating IRS1 at Ser(1101). J Biol Chem. 2004;279(44):45304-45307.
145. Xiao L, et al. Large adipocytes function as antigen- presenting cells to activate CD4(+) T cells via upregulating MHCII in obesity. Int J Obes (Lond). 2016;40(1):112-120.
146. Rhee SH, Jones BW, Toshchakov V, Vogel SN, Fenton MJ. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem. 2003;278(25):22506-22512.
147. Holland WL, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011;121(5):1858-1870.
148. Gorina R, Font-Nieves M, Marquez-Kisinousky L, Santalucia T, Planas AM. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFκB signaling, MAPK, and Jak1/Stat1 pathways. Glia. 2011;59(2):242-255.
149. Grzelkowska-Kowalczyk K, Wieteska-Skrzeczynska W. Treatment with IFN-γ prevents insulin- dependent PKB, p70S6k phosphorylation and protein synthesis in mouse C2C12 myogenic cells. Cell Biol Int. 2009;34(1):117-124.
150. Mashili F, Chibalin AV, Krook A, Zierath JR. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes. Diabetes. 2013;62(2):457-465.
151. White AT, LaBarge SA, McCurdy CE, Schenk S. Knockout of STAT3 in skeletal muscle does not prevent high-fat diet-induced insulin resistance. Mol Metab. 2015;4(8):569-575.
152. Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesityinduced insulin resistance. Front Endocrinol (Lausanne). 2012;3:181.
153. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24(12):5434-5446.
154. Rieusset J, et al. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes. 2004;53(9):2232-2241.
155. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277(44):42394-42398.
156. Jorgensen SB, et al. Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity. Diabetes. 2013;62(1):56-64.
157. Lebrun P, et al. Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice. Diabetologia. 2009;52(10):2201-2212.
158. Sachithanandan N, et al. Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance. Diabetes. 2011;60(8):2023-2031.
159. Sachithanandan N, et al. Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. Hepatology. 2010;52(5):1632-1642.
160. Cho KA, Kang PB. PLIN2 inhibits insulin-induced glucose uptake in myoblasts through the activation of the NLRP3 inflammasome. Int J Mol Med. 2015;36(3):839-844.
161. Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54(5):1566-1572.
162. Franckhauser S, et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia. 2008;51(7):1306-1316.
163. Kim HJ, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004;53(4):1060-1067.
164. Pierce JR, Maples JM, Hickner RC. IL-15 concentrations in skeletal muscle and subcutaneous adipose tissue in lean and obese humans: local effects of IL-15 on adipose tissue lipolysis. Am J Physiol Endocrinol Metab. 2015;308(12):E1131-E1139.
165. Itoh N. FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases. Front Endocrinol (Lausanne). 2014;5:107.
166. Moreno-Navarrete JM, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98(4):E769-E778.
167. Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012;287(15):11968-11980.
168. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes. 2009;58(1):30-38.